Opinion|Videos|March 28, 2024
BESPOKE CRC: The Impact of ctDNA-Guided Therapy in CRC
Focusing on the BESPOKE CRC study, John H. Strickler, MD, reviews recent updates presented at ASGO GI 2024 and discusses subset analyses from the trial.
Advertisement
Episodes in this series
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
2
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
3
CARTITUDE-2 Cohort A Follow-Up Data and Preparing Patients for CAR TCell Therapy
4
Referral Barriers to Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma
5